Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M., Sang S., Orindi B., Njau I., Karanja H., Kamau N., Gitonga JN., Mugo D., Wright D., Nyagwange J., Kutima B., Omuoyo D., Mwatasa M., Ngetsa C., Agoti C., Cheruiyot S., Nyaguara A., Munene M., Mturi N., Oloo E., Ochola-Oyier L., Mumba N., Mauncho C., Namayi R., Davies A., Tsofa B., Nduati EW., Aliyan N., Kasera K., Etyang A., Boyd A., Hill A., Gilbert S., Douglas A., Pollard A., Bejon P., Lambe T., Warimwe G.

DOI

10.12688/wellcomeopenres.19150.1

Type

Journal article

Publisher

F1000Research

Publication Date

2023-04-24T00:00:00+00:00

Volume

8

Keywords

32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Clinical Trials and Supportive Activities, Emerging Infectious Diseases, Clinical Research, Coronaviruses Vaccines, Coronaviruses, Prevention, Biotechnology, Patient Safety, Infectious Diseases, Vaccine Related, Immunization, 3.4 Vaccines, 6.1 Pharmaceuticals, Infection

Permalink More information Close